Insulin Makers Blame the Payment System for High List Prices

Drug Industry Daily
A A
Congress should eliminate copays for insulin rather than focus on the life-saving biologics’ list price, an executive with one of the nation’s largest drugmakers said Wednesday.

To View This Article:

Login

Subscribe To Drug Industry Daily